Skip to content

KLRS KLRS Other Income (Expense)

Other Income (Expense) at other companies

Eli Lilly logo
Eli LillyLLY
-$65M+72.8%
Amgen logo
AmgenAMGN
$75M-95.1%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$188.3M-39.9%
EyePoint, Inc.
 logo
EyePoint, Inc. EYPT
$2.34M-35.6%
Ocular Therapeutix logo
Ocular TherapeutixOCUL
$4.73M+3,576%
Kodiak Sciences Inc logo
Kodiak Sciences IncKOD
-$22K-320%

Other financials

Income statement

See full
Operating income-$11.8M-14.3%
Net income-$10.9M-6.5%
EPS (diluted)-$0.46+81.7%

Balance sheet

See full
Cash & equivalents$34.4M-65.9%
Total debt$1.4M
Total equity$68.6M+7.3%
Total assets$109.8M+6.5%

Cash flow

See full
Operating cash flow-$11.6M-55.6%
CapEx$17.0K
Free cash flow-$7.1M

Valuation

See full
Market cap$96.83M+136%
Enterprise value$63.82M

Returns & leverage

See full
Return on equity-66.6%
Debt / equity
Current ratio12.2×-2.1×

Where this comes from

Reported directly by KLRS in its filing.

Tagged under the XBRL concept us-gaap:NonoperatingIncomeExpense.

The official record: KLRS’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about KLRS's other income (expense).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is KLRS's other income (expense)?
KLRS (KLRS) reported other income (expense) of $977K in Q1 2026.
How has KLRS's other income (expense) changed year-over-year?
KLRS's other income (expense) increased by 518.4% year-over-year, from $158K to $977K.
What is the long-term trend for KLRS's other income (expense)?
Over 3 years (2021 to 2025), KLRS's other income (expense) has grown at a 3.4% compound annual growth rate (CAGR), from -$2.45M to $2.71M.
What does other income (expense) mean?
Net total of all non-operating income and expenses not classified in specific line items — a catch-all for miscellaneous financial items.